May 23, 2023 03:15 PM EDTUpdated June 12, 01:38 PM
Pharma
Law

Am­gen, Janssen reach set­tle­ment on Ste­lara biosim­i­lar drug, al­low­ing for 2025 launch at lat­est

Paul Schloesser

Associate Editor

Am­gen and Janssen set­tled their law­suit over a biosim­i­lar op­tion to J&J’s block­buster bi­o­log­ic Ste­lara — paving the way for the new­er drug to en­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Genen­tech vet launch­es ADC start­up with $20M

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times